Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash & Equivalents (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Cash & Equivalents for 7 consecutive years, with $294.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 4.6% to $294.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $294.9 million through Dec 2025, up 4.6% year-over-year, with the annual reading at $294.9 million for FY2025, 4.6% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $294.9 million at Beam Therapeutics, up from $268.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $612.0 million in Q3 2021, with the low at $97.2 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $298.9 million, with a median of $275.0 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents skyrocketed 343.81% in 2021, then crashed 74.43% in 2022.
  • Over 5 years, Cash & Equivalents stood at $560.0 million in 2021, then tumbled by 58.43% to $232.8 million in 2022, then surged by 87.27% to $435.9 million in 2023, then crashed by 35.31% to $282.0 million in 2024, then grew by 4.6% to $294.9 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $294.9 million, $268.0 million, and $282.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.